Success of susceptibility-guided eradication of Helicobacter pylori in a region with high secondary clarithromycin and levofloxacin resistance rates

doi:10.3748/wjg.v30.i2.184

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 30, Issue 2

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2811)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-6) series.

Item

Count

PDF

WORD

HTML

1172

Figures (1-3)

175

Tables (1-6)

156

Sum=1570

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

188

Download

319

Sum=507

Publishing Process of This Article

Item

Count

Browse

170

Download

462

Sum=632

Jan 14, 2024 (publication date) through Oct 3, 2024

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Gastroenterol. Jan 14, 2024; 30(2): 184-195
Published online Jan 14, 2024. doi: 10.3748/wjg.v30.i2.184

Table 6 Eradication rates of the susceptibility-guided and empiric treatment groups

	Susceptibility-guided treatment group	Empiric treatment group	P value
ITT analysis	75.5% (77/102)	59.0% (59/100)	0.001
PP analysis	90.6% (77/85)	70.2% (59/84)	0.012

ITT: Intention-to-treat analysis; PP: Per-protocol analysis.

Citation: Wang YM, Chen MY, Chen J, Zhang XH, Feng Y, Han YX, Li YL. Success of susceptibility-guided eradication of Helicobacter pylori in a region with high secondary clarithromycin and levofloxacin resistance rates. World J Gastroenterol 2024; 30(2): 184-195
URL: https://www.wjgnet.com/1007-9327/full/v30/i2/184.htm
DOI: https://dx.doi.org/10.3748/wjg.v30.i2.184